Skip to main content
Equibles
MBRX logo

MBRX · Moleculin Biotech, Inc. · Metrics

Track MBRX — free

Use MBRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research MBRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$6.50 +0.61 (+10.36%) At close · Oct 23
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As of June 30, 2026, the Company had an accumulated deficit of $226.5 million since inception and had not yet generated any revenues from operations. Additionally, management anticipates that its cash on hand of $7.3 million as of June 30, 2026, is not sufficient to fund its planned operations for a period of at least one year from when these condensed consolidated financial statements are issued. These factors raise substantial doubt regarding the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 13, 2026
Market Cap
$5.74M
Shares
973,869
Volume · Oct 23 27.74K Avg daily vol (4 sessions) 65.18K

MBRX metrics

53 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$6.50
Market cap
$5.74M

Price action

20 metrics
Price change (1W)
—
Price change (30D)
+5.0%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Beta
—
RSI (14D)
—
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
973,869

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.5
reciprocal yield 202.0%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-528.7%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2025-05-14

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$28.88M
Net income (TTM)
−$30.33M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-6,530.39
EBITDA per diluted share (TTM)
$-6,483.71
Net income per diluted share (TTM)
$-4,538.47
Operating cash flow per diluted share (TTM)
$-5,276.84
Free cash flow per diluted share (TTM)
$-5,281.82
Capital expenditures per diluted share (TTM)
$4.99
R&D per diluted share (TTM)
$4,122.00
Stock compensation per diluted share (TTM)
$656.31
Book value per share
$93.81

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+178.9%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-261.7%
Return on assets
-143.8%
Debt / equity
0.0
Current ratio
0.9
EBITDA (TTM)
−$28.83M
Free cash flow (TTM)
—
Quick ratio
0.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$7.26M
Latest balance sheet
Cash & equivalents
$7.26M
Total assets
$21.09M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$25.36M
Capital expenditures (TTM)
$0
R&D (TTM)
$19.68M
SG&A (TTM)
—
Stock compensation (TTM)
$1.58M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
18
13F filer change QoQ
-2
Institutional ownership
1.0%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
0.8%
Private-fund adviser ownership
0.3%
Active holders' share change QoQ
-53.8%
Holder tenure
10.6
Price vs estimated holder cost
+3.9%

Ownership (registered funds)

1 metrics
Index-fund ownership
0.3%

Short interest

3 metrics
Short interest
1.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
45 / 100

Insider activity

2 metrics
Net insider buying (90D)
$0
Insider-sentiment score
87 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1659617 CUSIP 60855D408 13F (30d) 1 filings 1 filers Visit website Investor relations